Gene therapy for vision loss: Long-Term safety check begins
Disease control
Ongoing
This study is a long-term safety check for 18 patients who previously received an experimental gene therapy called RetinoStat for wet age-related macular degeneration, a leading cause of vision loss. The main goal is to monitor these patients for any long-term side effects after …
Phase: PHASE1 • Sponsor: Oxford BioMedica • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC